文献速递胸部肿瘤

多中心、III期、随机、双盲、安慰剂对照试验:普伐他汀联合一线标准化疗治疗小细胞肺癌(LUNGSTAR)

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
PubMed 文献 · J Clin Oncol · 2017-02-27

LUNGSTAR研究纳入846例确诊小细胞肺癌(局限期或广泛期)、体能状态0-3分的患者,随机接受普伐他汀40 mg每日一次或安慰剂,联合最多6周期依托泊苷+顺铂或卡铂每3周一次,直至疾病进展或不可耐受毒性。主要终点总生存(OS)无获益:普伐他汀组 vs 安慰剂组2年OS率13.2% vs 14.1%,HR 1.01(95%CI 0.88-1.16;P=.90);中位OS 10.7个月 vs 10.6个月。结论:普伐他汀40 mg联合标准治疗虽安全但无获益。

要点

  • 普伐他汀组 vs 安慰剂组2年OS率13.2% vs 14.1%,HR 1.01(95%CI 0.88-1.16;P=.90),无获益。
  • 中位OS普伐他汀组10.7个月 vs 安慰剂组10.6个月;中位PFS 7.7个月 vs 7.3个月。
  • 不良事件两组相似;局限期疾病中位OS两组均为14.6个月,广泛期9.1个月 vs 8.8个月。

核心结论

  • 普伐他汀40 mg联合标准小细胞肺癌治疗虽安全,但患者无获益。
  • 作者结论与所有四项专门评估他汀治疗癌症患者的更小规模随机安慰剂对照试验一致。

研究设计与样本

  • 多中心、III期、随机、双盲、安慰剂对照试验,纳入846例来自91家英国医院的确诊小细胞肺癌(局限期或广泛期)、体能状态0-3分患者。
  • 患者随机接受普伐他汀40 mg每日一次或安慰剂,联合最多6周期依托泊苷+顺铂或卡铂每3周一次,直至疾病进展或不可耐受毒性。
  • 主要终点为总生存(OS),次要终点为无进展生存(PFS)、缓解率和毒性。

主要发现

  • 共发生758例死亡和787例PFS事件;普伐他汀在所有患者及多个亚组中均未显示获益。
  • 普伐他汀组 vs 安慰剂组2年OS率13.2%(95%CI 10.0-16.7) vs 14.1%(95%CI 10.9-17.7),HR 1.01(95%CI 0.88-1.16;P=.90)。
  • 中位OS普伐他汀组10.7个月 vs 安慰剂组10.6个月;中位PFS 7.7个月 vs 7.3个月。
  • 局限期疾病中位OS两组均为14.6个月;广泛期疾病中位OS普伐他汀组9.1个月 vs 安慰剂组8.8个月。
  • 不良事件两组相似。

关键数值与推荐

  • 普伐他汀40 mg每日一次联合最多6周期依托泊苷+顺铂或卡铂每3周一次。
  • 主要终点OS:2年OS率普伐他汀组13.2% vs 安慰剂组14.1%,HR 1.01(95%CI 0.88-1.16;P=.90)。
  • 中位OS普伐他汀组10.7个月 vs 安慰剂组10.6个月;中位PFS 7.7个月 vs 7.3个月。
  • 局限期疾病中位OS两组均为14.6个月;广泛期疾病中位OS普伐他汀组9.1个月 vs 安慰剂组8.8个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and prolong life in several cancer types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically SCLC. Patients and Methods Patients with confirmed SCLC (limited or extensive disease) and performance status 0 to 3 were randomly assigned to receive daily pravastatin 40 mg or placebo, combined with up to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerable toxicity. Primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), response rate, and toxicity. Results Eight hundred forty-six patients from 91 United Kingdom hospitals were recruited. The median age of recruited patients was 64 years of age, 43% had limited disease, and 57% had extensive disease. There were 758 deaths and 787 PFS events. No benefit was found for pravastatin, either in all patients or in several subgroups. For pravastatin versus placebo, the 2-year OS rate was 13.2% (95% CI, 10.0 to 16.7) versus 14.1% (95% CI, 10.9 to 17.7), respectively, with a hazard ratio of 1.01 (95% CI, 0.88 to 1.16; P = .90. The median OS was 10.7 months v 10.6 months, respectively. The median PFS was 7.7 months v 7.3 months, respectively. The median OS (pravastatin v placebo) was 14.6 months in both groups for limited disease and 9.1 months versus 8.8 months, respectively, for extensive disease. Adverse events were similar between groups. Conclusion Pravastatin 40 mg combined with standard SCLC therapy, although safe, does not benefit patients. Our conclusions are the same as those found in all four much smaller, randomized, placebo-controlled trials specifically designed to evaluate statin therapy in patients with cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017. PMID: 28240967. doi:10.1200/JCO.2016.69.7391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。